Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




May
08
Today In Oncology
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
Tiragolumab Plus Atezolizumab and Chemotherapy in Advanced Nonsquamous NSCLC
Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing CRS
High YAP1 Expression Leads to Chemotherapy Resistance Relapse in Treated SCLC
AI Pathology Framework for Biological Understanding of Tumors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo